Show simple item record

dc.contributor.authorZee, Ying-Kiat
dc.contributor.authorO'Connor, James P B
dc.contributor.authorParker, Geoff J M
dc.contributor.authorJackson, Alan
dc.contributor.authorClamp, Andrew R
dc.contributor.authorTaylor, Malcolm B
dc.contributor.authorClarke, Noel W
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2010-02-24T10:25:22Z
dc.date.available2010-02-24T10:25:22Z
dc.date.issued2010-02
dc.identifier.citationImaging angiogenesis of genitourinary tumors. 2010, 7 (2):69-82 Nat Rev Urolen
dc.identifier.issn1759-4820
dc.identifier.pmid20084077
dc.identifier.doi10.1038/nrurol.2009.262
dc.identifier.urihttp://hdl.handle.net/10541/92854
dc.description.abstractAngiogenesis is a key process in the growth and metastasis of cancer, and genitourinary tumors are no exception. The evolution of angiogenesis as an important target for novel anticancer therapeutics has brought with it new challenges for in vivo imaging. Most imaging techniques quantify physiological parameters, such as blood volume and capillary endothelial permeability. Although CT, PET and ultrasonography have shown promise, MRI is the most common method used to evaluate angiogenesis in clinical trials of genitourinary tumors. Pilot studies of MRI, CT and ultrasonography in patients with renal cancer have produced promising results; reductions in vascular permeability and blood flow have been correlated with progression-free survival. The vascular characteristics of prostate cancer have been evaluated by MRI, and this has been suggested as a means of assessing tumor response to hormone deprivation therapy. Current evidence highlights the potential of angiogenesis imaging in the diagnosis, staging and possibly response monitoring of bladder cancer. In the future, assessment of the angiogenic process at the structural, functional and molecular levels, before, during and after antiangiogenic therapy will undoubtedly be integrated into wider clinical practice.
dc.language.isoenen
dc.subjectCanceren
dc.subjectGenitourinary Tumoursen
dc.subjectAnticancer Therapyen
dc.subjectAngiogenesisen
dc.subjectIn Vivo Imagingen
dc.titleImaging angiogenesis of genitourinary tumors.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.en
dc.identifier.journalNature Reviews. Urologyen
html.description.abstractAngiogenesis is a key process in the growth and metastasis of cancer, and genitourinary tumors are no exception. The evolution of angiogenesis as an important target for novel anticancer therapeutics has brought with it new challenges for in vivo imaging. Most imaging techniques quantify physiological parameters, such as blood volume and capillary endothelial permeability. Although CT, PET and ultrasonography have shown promise, MRI is the most common method used to evaluate angiogenesis in clinical trials of genitourinary tumors. Pilot studies of MRI, CT and ultrasonography in patients with renal cancer have produced promising results; reductions in vascular permeability and blood flow have been correlated with progression-free survival. The vascular characteristics of prostate cancer have been evaluated by MRI, and this has been suggested as a means of assessing tumor response to hormone deprivation therapy. Current evidence highlights the potential of angiogenesis imaging in the diagnosis, staging and possibly response monitoring of bladder cancer. In the future, assessment of the angiogenic process at the structural, functional and molecular levels, before, during and after antiangiogenic therapy will undoubtedly be integrated into wider clinical practice.


This item appears in the following Collection(s)

Show simple item record